Last reviewed · How we verify
CNGRC peptide-TNF alpha conjugate — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
CNGRC peptide-TNF alpha conjugate (CNGRC peptide-TNF alpha conjugate) — European Organisation for Research and Treatment of Cancer - EORTC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CNGRC peptide-TNF alpha conjugate TARGET | CNGRC peptide-TNF alpha conjugate | European Organisation for Research and Treatment of Cancer - EORTC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CNGRC peptide-TNF alpha conjugate CI watch — RSS
- CNGRC peptide-TNF alpha conjugate CI watch — Atom
- CNGRC peptide-TNF alpha conjugate CI watch — JSON
- CNGRC peptide-TNF alpha conjugate alone — RSS
Cite this brief
Drug Landscape (2026). CNGRC peptide-TNF alpha conjugate — Competitive Intelligence Brief. https://druglandscape.com/ci/cngrc-peptide-tnf-alpha-conjugate. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab